Patricia A Seymour Selected Research

Patricia A Seymour Research Topics

7	Schizophrenia (Dementia Praecox) 05/2015 - 03/2010
4	Cognitive Dysfunction 08/2014 - 03/2010
2	Neurodegenerative Diseases (Neurodegenerative Disease) 05/2012 - 04/2002
2	Alzheimer Disease (Alzheimer's Disease) 12/2002 - 04/2002
1	Neurobehavioral Manifestations 09/2013
1	Alcoholism (Alcohol Abuse) 10/2009
1	Catalepsy 02/2007
1	Infarction (Infarctions) 01/2003
1	Brain Ischemia (Cerebral Ischemia) 01/2003
1	Substance-Related Disorders (Drug Abuse) 01/2003
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2003
1	Seizures (Absence Seizure) 01/2003
1	Ischemia 01/2003

3	N-Methylaspartate (NMDA)IBA 09/2013 - 01/2003
3	Ketamine FDA LinkGeneric 09/2010 - 03/2010
2	Antipsychotic Agents (Antipsychotics)IBA 05/2014 - 06/2010
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 10/2011 - 06/2010
2	alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)IBA 09/2010 - 01/2003
2	AMPA Receptors (AMPA Receptor)IBA 09/2010 - 01/2003
1	SulfonamidesIBA 05/2015
1	tetrahydrofuranIBA 05/2015
1	PropaneIBA 05/2015
1	Kynurenic Acid (Kynurenate)IBA 08/2014
1	Glutamic Acid (Glutamate)FDA Link 08/2014
1	Dopamine Agonists (Dopamine Agonist)IBA 09/2013
1	Neurotransmitter Agents (Neurotransmitter)IBA 05/2012
1	EnzymesIBA 10/2011
1	D-Amino-Acid Oxidase (D-Amino Acid Dehydrogenase)IBA 10/2011
1	Serine (L-Serine)FDA Link 10/2011
1	1-methyl-1H-imidazole-4-carboxylic acid (3- chloro- 4- fluoro- benzyl)- (3- methyl- 3- aza- bicyclo(3.1.0) hex-6-ylmethyl)amideIBA 03/2010
1	Glycine Plasma Membrane Transport ProteinsIBA 03/2010
1	Varenicline (Chantix)FDA Link 10/2009
1	CP-809,101IBA 02/2007
1	CP 154526IBA 01/2003
1	CRF receptor type 1IBA 01/2003
1	CP 465,022IBA 01/2003
1	Glutamate Receptors (Glutamate Receptor)IBA 01/2003
1	Kainic Acid (Kainate)IBA 01/2003
1	Pharmaceutical PreparationsIBA 12/2002
1	CyclinsIBA 12/2002
1	tau Proteins (tau Protein)IBA 04/2002
1	Protein Kinases (Protein Kinase)IBA 04/2002
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 04/2002

1	Therapeutics 09/2013